微创机器人-B(02252.HK)今日盘中大涨5.03%,引发市场广泛关注。
公司公告显示,其自主研发的图迈单臂单孔腔镜手术机器人(简称"图迈单臂")获得了国家药品监督管理局(NMPA)的注册批准。这表明图迈单臂的整体性能、创新水平、临床有效性及安全性已通过权威部门的认证,成为拥有完全自主知识产权的单臂腔镜机器人。
图迈单臂作为微创机器人的核心产品图迈腔镜手术机器人的同系列产品,具有独特的单臂结构,可在狭小空间灵活操作,同时以单孔方式完成腹腔镜手术。与传统多孔手术相比,图迈单臂具有伤口小、疼痛轻、术后美观度高等临床优势。该款产品的获批将进一步丰富微创机器人的产品线,增强其在国内外市场的竞争力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.